These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24865526)

  • 1. Limited granulomatosis with polyangiitis in an adolescent with Crohn's disease on infliximab therapy: cause or coincidence?
    Arora H; Madani S; Debelenko LV; McGrath EJ; Mutyala R; Guglani L
    Clin Respir J; 2015 Oct; 9(4):506-11. PubMed ID: 24865526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of pulmonary adverse effects of infliximab therapy in Crohn's disease.
    Patel D; Madani S; Patel S; Guglani L
    Expert Opin Drug Saf; 2016 Jun; 15(6):769-75. PubMed ID: 26923135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.
    Papamichael K; Vande Casteele N; Gils A; Tops S; Hauenstein S; Singh S; Princen F; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1103-10. PubMed ID: 25478919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-occurrence of oral pemphigus vulgaris and herpes simplex virus infection in a young patient with Crohn's disease: report of a rare case of oral lesions during anti-TFN alpha and immunomodulator therapy.
    Lopes DN; de Oliveira NP; de Campos Augusto KC; Milagres A; Miguez AL; Junior AS; Conde DC; Cunha KS; Magalhães MH; Rozza-de-Menezes RE
    Int J Colorectal Dis; 2024 Aug; 39(1):125. PubMed ID: 39105861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary necrobiotic nodules in Crohn's disease: a rare extra-intestinal manifestation.
    El-Kersh K; Fraig M; Cavallazzi R; Saad M; Perez RL
    Respir Care; 2014 Dec; 59(12):e190-2. PubMed ID: 25233391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous development of sarcoidosis and cutaneous vasculitis in a patient with refractory Crohn's disease during infliximab therapy.
    Numakura T; Tamada T; Nara M; Muramatsu S; Murakami K; Kikuchi T; Kobayashi M; Muroi M; Okazaki T; Takagi S; Eishi Y; Ichinose M
    BMC Pulm Med; 2016 Feb; 16():30. PubMed ID: 26864464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis.
    Fraser D; Boyle S; Amft N
    J Rheumatol; 2016 Dec; 43(12):2199-2200. PubMed ID: 27909145
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy].
    Park SH; Jeen YT; Chun HR; Kim DI; Baeck CW; Kim YS; Chun HJ; Lee HS; Um SH; Choi JH; Kim CD; Ryu HS; Hyun JH
    Korean J Gastroenterol; 2005 Oct; 46(4):297-301. PubMed ID: 16247274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa.
    Yu L; Yang X; Xia L; Zhong J; Ge W; Wu J; Liu H; Liu F; Liu Z
    Mediators Inflamm; 2015; 2015():793764. PubMed ID: 25873771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral Sub-deltoid Bursitis in a Patient Receiving Infliximab for Crohn's Disease.
    Bellakhal S; Abbes M; Jomni MT; Abdelaali I; Charfi M; Douggui MH
    Curr Drug Saf; 2020; 15(1):77-80. PubMed ID: 31483235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].
    Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW
    Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bowel Perforation Associated With Infliximab Use in a Pediatrics Patient.
    Joshi A; Bajwa R; Bhattacharjee N; Bodicharla R
    WMJ; 2016 Apr; 115(2):90-2. PubMed ID: 27197343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case records of the Massachusetts General Hospital. Case 39-2014. A 9-year-old girl with Crohn’s disease and pulmonary nodules.
    Nelson BA; Kaplan JL; El Saleeby CM; Lu MT; Mark EJ
    N Engl J Med; 2014 Dec; 371(25):2418-27. PubMed ID: 25517709
    [No Abstract]   [Full Text] [Related]  

  • 16. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of infliximab in treatment of pediatric Crohn's disease in China].
    Luo Y; Yu J; Zhao H; Peng K; Lou J; Ma M; Chen J
    Zhonghua Er Ke Za Zhi; 2014 Sep; 52(9):688-92. PubMed ID: 25476432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
    Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
    Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.